Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.

ABSTRACT:

Objective

To evaluate rates of serious organ specific immune-related adverse events, general adverse events related to immune activation, and adverse events consistent with musculoskeletal problems for anti-programmed cell death 1 (PD-1) drugs overall and compared with control treatments.

Design

Systematic review and meta-analysis.

Data sources

Medline, Embase, Cochrane Library, Web of Science, and Scopus searched to 16 March 2017 and combined with data from ClinicalTrials.gov.

Study selection

Eligible studies included primary clinical trial data on patients with cancer with recurrent or metastatic disease.

Data extraction

Three independent investigators extracted data on adverse events from ClinicalTrials.gov and the published studies. Risk of bias was

SUBMITTER: Baxi S 

PROVIDER: S-EPMC5851471 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature